article thumbnail

Presence of Diabetic Retinopathy Worsens Vision-Related Quality of Life

HCPLive

As diabetic retinopathy severity progresses, both vision-related and health-related scales show a significant deterioration in quality of life scores.

article thumbnail

Diabetes Dialogue: Blue Circle Health, with Monica Gomberg, MD

HCPLive

Monica Gomberg, MD, joins the podcast to discuss how Blue Circle Health leverages free support and education programs to improve management and quality of life in people with types 1 diabetes.

article thumbnail

LX9211 Reduces Diabetic Nerve Pain, Improves Quality of Life in Phase 2 Trial

HCPLive

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.

article thumbnail

Semaglutide and Walking Capacity in People With Symptomatic Peripheral Artery Disease and Type 2 Diabetes

American College of Cardiology

The goal of the phase 3b STRIDE trial was to evaluate the safety of once-weekly injections of the GLP-1 receptor agonist semaglutide and to determine whether it improves function (symptoms and quality of life [QoL]) in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes (T2D) with functional limitations.

article thumbnail

CareDx Launches Two Expanded Indications for AlloSure Testing Services

DAIC

Simultaneous pancreas-kidney (SPK) transplants are known to improve the quality of life and long-term survival of patients with insulin dependent diabetes and advanced renal disease. I have witnessed firsthand the significant benefits for patients with diabetes and kidney failure of receiving a pancreas and kidney transplant.

article thumbnail

Quality of Life in Elderly Diabetic Coronary Patients

The American Journal of Cardiology

Publication date: Available online 15 June 2024 Source: The American Journal of Cardiology Author(s): Monique G. Davis, James C. Blankenship

article thumbnail

STRIDE and SOUL: Semaglutide Improves PAD Outcomes; Oral Formulation Effective

American College of Cardiology

Semaglutide, compared to placebo, significantly improved walking distance, symptoms and quality of life in participants with symptomatic peripheral artery disease (PAD) and type 2 diabetes (T2D), according to results of the STRIDE study presented at ACC.25 25 in Chicago and simultaneously published in The Lancet.